tiprankstipranks
Trending News
More News >
Eurofins Scientific (FR:ERF)
:ERF
Advertisement

Eurofins Scientific (ERF) AI Stock Analysis

Compare
35 Followers

Top Page

FR:ERF

Eurofins Scientific

(LSE:ERF)

Rating:64Neutral
Price Target:
€68.00
▲(3.19%Upside)
Eurofins Scientific's overall stock score is primarily driven by strong financial performance and positive technical indicators. However, the high P/E ratio and overbought technical signals slightly detract from the potential attractiveness of the stock.

Eurofins Scientific (ERF) vs. iShares MSCI France ETF (EWQ)

Eurofins Scientific Business Overview & Revenue Model

Company DescriptionEurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
How the Company Makes MoneyEurofins Scientific makes money primarily through its extensive network of laboratories that provide analytical testing services. The company generates revenue by offering specialized testing and support services to a diverse set of industries, including pharmaceuticals, food and feed testing, environment testing, and consumer product testing. Key revenue streams include fees for conducting laboratory tests, providing analytical tools and services, and offering consultancy services related to regulatory compliance and quality assurance. Eurofins also benefits from strategic acquisitions and partnerships, which expand its service offerings and geographic presence, contributing to its overall earnings.

Eurofins Scientific Financial Statement Overview

Summary
Eurofins Scientific is in a strong financial position with consistent revenue growth and profitability. Robust cash flow generation supports future growth opportunities, although slight leverage increase is noted.
Income Statement
75
Positive
Eurofins Scientific exhibits strong profitability with a gross profit margin consistently above 60%. The company demonstrated a notable revenue growth rate of 6.7% in 2024, recovering from a slight decline in 2023. However, EBIT for 2024 was missing, limiting assessment in that area. Net profit margin increased to 5.8% in 2024, indicating improving efficiency.
Balance Sheet
70
Positive
The balance sheet shows a solid equity base with an equity ratio of 49.0% in 2024, reflecting financial stability. However, the debt-to-equity ratio increased slightly to 0.68, which suggests a moderate level of leverage. Return on equity improved to 7.6% in 2024, indicating efficient use of equity capital.
Cash Flow
80
Positive
Eurofins Scientific's cash flow statement reflects robust operating cash flows, with an increase to €1.32 billion in 2024. The free cash flow to net income ratio is healthy, demonstrating strong cash generation relative to net income. Free cash flow grew significantly by 68.9% in 2024, highlighting improved liquidity and potential for reinvestment.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.95B6.51B6.71B6.72B5.44B
Gross Profit4.71B620.40M4.49B4.57B3.69B
EBITDA1.38B1.22B1.36B1.71B1.28B
Net Income406.40M310.30M610.20M782.60M539.40M
Balance Sheet
Total Assets10.89B10.89B10.08B9.33B8.58B
Cash, Cash Equivalents and Short-Term Investments613.90M1.22B486.60M515.30M912.40M
Total Debt3.61B3.93B3.33B2.75B3.15B
Total Liabilities5.50B5.75B5.23B4.66B4.86B
Stockholders Equity5.34B5.08B4.78B4.65B3.69B
Cash Flow
Free Cash Flow790.50M467.80M476.10M990.30M868.00M
Operating Cash Flow1.32B1.02B1.14B1.51B1.22B
Investing Cash Flow-846.50M-681.10M-855.90M-1.03B-525.00M
Financing Cash Flow-1.09B495.80M-311.30M-910.30M-48.60M

Eurofins Scientific Technical Analysis

Technical Analysis Sentiment
Positive
Last Price65.90
Price Trends
50DMA
59.51
Positive
100DMA
55.29
Positive
200DMA
51.67
Positive
Market Momentum
MACD
1.15
Negative
RSI
81.76
Negative
STOCH
87.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 65.9 is above the 20-day moving average (MA) of 61.13, above the 50-day MA of 59.51, and above the 200-day MA of 51.67, indicating a bullish trend. The MACD of 1.15 indicates Negative momentum. The RSI at 81.76 is Negative, neither overbought nor oversold. The STOCH value of 87.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.

Eurofins Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
€11.54B27.0211.27%0.91%6.25%18.93%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
€14.42B33.1410.86%0.74%
€9.19B26.108.89%1.26%
€16.82B74.685.71%0.40%
€253.64M62.332.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ERF
Eurofins Scientific
65.90
12.78
24.06%
GB:0RUG
bioMerieux
124.38
27.38
28.23%
GB:0MH6
Ipsen
111.10
9.48
9.33%
GB:0RG8
Sartorius Stedim Biotech
175.25
0.73
0.42%
DE:E8TN
Eurobio-Scientific SA
24.85
8.45
51.52%
DE:ZEP2
Eurofins-Cerep SA
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025